Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
about
Interventions for reducing inflammation in familial Mediterranean feverInterventions for reducing inflammation in familial Mediterranean feverFamilial Mediterranean fever: current perspectivesEULAR recommendations for the management of familial Mediterranean feverThe challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndromeEvasion of inflammasome activation by microbial pathogensPotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.IL-1 blockade in autoinflammatory syndromes.Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesCanakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatmentTargeting the inflammasome in rheumatic diseases.Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverMolecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersMonogenic autoinflammatory diseases: concept and clinical manifestations.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Familial Mediterranean fever: An updated review.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Treating inflammation by blocking interleukin-1 in humans.Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for ManagementUnexplained recurrent fever: when is autoinflammation the explanation?Canakinumab in pediatric rheumatic diseases.Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.Clinical Review: Familial Mediterranean Fever-An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment.The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.The myths we believed in familial Mediterranean fever: what have we learned in the past years?Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.Treatment of adult-onset still's disease: up to date.Biologic therapy in familial Mediterranean fever.Canakinumab for the treatment of familial Mediterranean fever.Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF).International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases.
P2860
Q24187197-9BEBD3A5-8587-47AD-A9A5-97538B468D16Q24201537-0DBADBF1-D38C-4404-83EF-3C2AA02483B2Q26751292-B0D6B20E-9BA2-4029-9976-C2EEB4AA7D6DQ26775286-754DBA8C-CF12-43E3-837B-9FA87CA0F839Q28070297-7E297F1E-52FC-439C-A26B-FB450650F079Q28082757-F5B91597-BC87-4577-842A-E3A406F2F883Q33710807-D97B9036-CE77-4287-BF70-DB93FF956DA8Q34039381-D31834ED-9DB9-4393-8585-086DAD50A687Q34262561-5C3FD78E-91F5-411A-9AE5-1F4C278A966AQ34607687-2375FED6-609D-4850-B0A7-E483FD1938ADQ35133812-1C845667-EFB9-4DD3-A0FC-0B70BF2711FFQ35535362-61CBBDFB-1EE5-4194-AE04-5DA24AFF8779Q35804717-6DE859BA-2ABD-4205-AC7E-E63220E08449Q36027314-2F69E1E7-418C-4FBF-ACE1-35BECB353A9CQ36041225-29908DA4-420E-48E1-8717-77825449DAA7Q36798016-1D1E8C01-6FE6-489C-BE58-1448F9611F27Q37077564-EFB45BC1-3E26-44D4-AA21-855E1B091BCEQ37162157-025646FE-3CC2-4427-914F-F28A0DB38FAEQ37270409-6783FAD6-9B3E-419A-966D-27A640C8971CQ37296449-8FA5BD23-F139-4F74-96C1-F63D31116202Q37466515-003A48EB-8CB1-405F-B27A-A5F8A56E2A97Q37636664-CB2F8075-5806-4342-821E-606048DB03B7Q37716794-14B9DFE0-0C97-41AE-90F7-19DB92941845Q38075002-FB218271-975B-4D67-A5DF-061D2A390CA1Q38085662-42716298-1536-4307-9BDF-F0F0CF30936AQ38122566-E376E595-F805-4CC8-82FD-9F0E9F6C26E1Q38151758-019CBB8C-7A86-43A1-8342-429C4BAF475BQ38161412-83B2D9D9-EB63-4C78-B31D-296C78656915Q38241480-849C03E3-A4A9-454E-9C62-A2AD9FB03647Q38365710-1498EEFC-701B-40F1-B31E-E65B6B4C467EQ38373888-B4792D71-0CBB-4FD1-9372-D92CFCC887D4Q38389302-3D2BD054-6E8B-4DC9-BF3B-C95DBEAF224DQ38400573-E9590236-3BE2-485D-9F54-2D52D6480BFFQ38674665-6EF49E0A-1B6B-41BB-922E-1E10824D1115Q38679486-2B92EDA9-D9B2-4958-A230-0F67D6FC8B53Q38759360-21A1CBC8-8AEE-4688-B038-6BD185CA2E49Q38865019-BCBEAD51-FC34-4F59-9839-BEAF99EAC9A5Q38914751-FED4DF7B-05E3-464D-8FD1-B1FF9A158A6AQ38977041-EF620019-4218-4DA6-A2C7-6ACA2F38511AQ39132605-4B39E269-0F45-4A40-8C7C-EE5BAF78413B
P2860
Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rilonacept for colchicine-resi ...... ean fever: a randomized trial.
@en
type
label
Rilonacept for colchicine-resi ...... ean fever: a randomized trial.
@en
prefLabel
Rilonacept for colchicine-resi ...... ean fever: a randomized trial.
@en
P2093
P1476
Rilonacept for colchicine-resi ...... nean fever: a randomized trial
@en
P2093
Andreas O Reiff
Anne Johnson
Daniel J Lovell
Daniel L Kastner
Dowain A Wright
Edward H Giannini
Grace Park
Karyl S Barron
Michael H Weisman
P304
P356
10.7326/0003-4819-157-8-201210160-00003
P407
P577
2012-10-01T00:00:00Z